Should I buy or sell Ocuphire Pharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocuphire Pharma in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUP shares. View OCUP analyst ratings or view top-rated stocks .

What is Ocuphire Pharma's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price targets for Ocuphire Pharma's shares. Their OCUP share price targets range from $17.00 to $20.00. On average, they expect the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 983.8% from the stock's current price. View analysts price targets for OCUP or view top-rated stocks among Wall Street analysts .

How have OCUP shares performed in 2024?

Ocuphire Pharma's stock was trading at $3.01 at the start of the year. Since then, OCUP stock has decreased by 42.5% and is now trading at $1.73. View the best growth stocks for 2024 here .

When is Ocuphire Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our OCUP earnings forecast .

How were Ocuphire Pharma's earnings last quarter?

Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its earnings results on Friday, March, 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.14. The business had revenue of $1.69 million for the quarter, compared to analyst estimates of $3.47 million. Ocuphire Pharma had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 24.57%.

Who are Ocuphire Pharma's major shareholders?

Ocuphire Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.87%), Rice Hall James & Associates LLC (1.18%), Richmond Brothers Inc. (0.89%), Empowered Funds LLC (0.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include George Magrath, James S J Manuso , Jay Pepose , Joseph K Schachle, Mina Sooch and Nirav S Jhaveri. View institutional ownership trends .

How do I buy shares of Ocuphire Pharma?

Shares of OCUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OCUP

Ocuphire Pharma (OCUP) Stock Price, News & Analysis

→ Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad)

Free OCUP Stock Alerts

$1.77

+0.09 (+5.04%)

(As of 01:27 PM ET)

Compare

Today's Range: $1.70
▼
$1.85
50-Day Range: $1.51
▼
$2.23
52-Week Range: $1.50
▼
$4.58

Volume: 179,511 shs
Average Volume: 213,206 shs
Market Capitalization: $45.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.75

Ocuphire Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.20 Rating Score
Upside/Downside: 983.8% Upside
$18.75 Price Target
Short Interest: Healthy
4.71% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.31
Based on 14 Articles This Week
Insider Trading: Acquiring Shares
$74,100 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.16) to ($0.52) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.95 out of 5 stars

Medical Sector

379th out of 918 stocks

Pharmaceutical Preparations Industry

168th out of 429 stocks

3.6

Analyst's Opinion

Consensus Rating
Ocuphire Pharma has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ocuphire Pharma has only been the subject of 4 research reports in the past 90 days.
Read more about Ocuphire Pharma's stock forecast and price target.

4.0

Short Interest

Percentage of Shares Shorted
4.71% of the outstanding shares of Ocuphire Pharma have been sold short.
Short Interest Ratio / Days to Cover
Ocuphire Pharma has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Ocuphire Pharma has recently decreased by 22.78%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ocuphire Pharma does not currently pay a dividend.
Dividend Growth
Ocuphire Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OCUP.

1.5

News and Social Media Coverage

News Sentiment
Ocuphire Pharma has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Ocuphire Pharma this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for OCUP on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
4 people have added Ocuphire Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ocuphire Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $74,100.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.70% of the stock of Ocuphire Pharma is held by insiders.
Percentage Held by Institutions
Only 14.97% of the stock of Ocuphire Pharma is held by institutions.
Read more about Ocuphire Pharma's insider trading history.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Ocuphire Pharma are expected to grow in the coming year, from ($1.16) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ocuphire Pharma is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ocuphire Pharma is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ocuphire Pharma has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
Read more about Ocuphire Pharma's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Everybody laughed when he recommended Netflix

"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined.

Click here to see how it could become the No. 1 investment of the next decade.

About Ocuphire Pharma Stock (NASDAQ:OCUP)

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

OCUP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OCUP Stock News Headlines

May 16, 2024 | americanbankingnews.com

Q2 2024 Earnings Estimate for Ocuphire Pharma, Inc. Issued By HC Wainwright (NASDAQ:OCUP)

May 16, 2024 | americanbankingnews.com

Ocuphire Pharma, Inc. (NASDAQ:OCUP) to Post FY2028 Earnings of $1.74 Per Share, HC Wainwright Forecasts

May 16, 2024 | americanbankingnews.com

Canaccord Genuity Group Upgrades Ocuphire Pharma (NASDAQ:OCUP) to "Strong-Buy"

May 15, 2024 | americanbankingnews.com

Canaccord Genuity Group Cuts Ocuphire Pharma (NASDAQ:OCUP) Price Target to $18.00

May 15, 2024 | americanbankingnews.com

Ocuphire Pharma (NASDAQ:OCUP) Rating Reiterated by HC Wainwright

May 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Ocuphire Pharma’s APX3330 Shows Promise for Diabetic Retinopathy and Pipeline Progress

May 12, 2024 | finance.yahoo.com

Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations

May 10, 2024 | investorplace.com

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024

May 10, 2024 | globenewswire.com

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

May 6, 2024 | globenewswire.com

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

May 3, 2024 | globenewswire.com

Ocuphire Pharma to Present at the Aegis Virtual Conference

April 24, 2024 | finance.yahoo.com

Ocuphire Pharma, Inc. (OCUP)

April 22, 2024 | globenewswire.com

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

April 11, 2024 | globenewswire.com

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

April 1, 2024 | markets.businessinsider.com

Ocuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner Viatris

April 1, 2024 | globenewswire.com

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

March 27, 2024 | investing.com

Ocuphire Pharma COO acquires $4.1k in company stock

March 15, 2024 | investorplace.com

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023

March 13, 2024 | finance.yahoo.com

Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment

March 10, 2024 | finance.yahoo.com

Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations

March 8, 2024 | globenewswire.com

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

March 4, 2024 | msn.com

Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

February 26, 2024 | investorplace.com

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

February 23, 2024 | globenewswire.com

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

See More Headlines

Company Calendar

Last Earnings: 3/08/2024
Today: 5/20/2024
Next Earnings (Estimated): 8/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OCUP
CUSIP: N/A
CIK: 1228627
Web: www.ocuphire.com
Phone: (248) 681-9815
Fax: 240-268-5310
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.75
High Stock Price Target: $20.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +1,012.8%
Consensus Rating: Buy
Rating Score (0-4): 3.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,990,000.00
Net Margins: -59.44%
Pretax Margin: -59.38%
Return on Equity: -24.57%
Return on Assets: -22.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.96
Quick Ratio: 13.35

Sales & Book Value

Annual Sales: $19.05 million
Price / Sales: 2.29
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.78 per share
Price / Book: 0.95

Miscellaneous

Outstanding Shares: 25,920,000
Free Float: 23,669,000
Market Cap: $43.68 million
Optionable: Optionable
Beta: 0.39

Key Executives

Mr. Richard J. Rodgers M.B.A. (Age 57)
Interim President & Director
Comp: $62k
Mr. Bernhard Hoffmann M.B.A. (Age 68)
Senior Vice President of Corporate Development & Operations and Secretary
Comp: $348.96k
Ms. Amy Zaremba Rabourn C.P.A. (Age 43)
MAcc, Senior Vice President of Finance
Comp: $384.52k
Mr. George Magrath M.B.A.
M.D., M.S., CEO & Director
Mr. Nirav Suresh Jhaveri C.F.A.
Chief Financial Officer
Mr. Joseph K. Schachle MBA (Age 59)
Chief Operating Officer
Dr. Ashwath Jayagopal Ph.D.
Chief Scientific & Development Officer
Dr. Daniela C. Oniciu Ph.D.
Global Head of R&D, Chemistry and Product Development
Dr. Mitchell Brigell Ph.D.
Head of Clinical Development & Strategy
Mr. Chris Ernst
Global Head of QA & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCUP Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocuphire Pharma stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocuphire Pharma in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUP shares.
View OCUP analyst ratings or view top-rated stocks.
What is Ocuphire Pharma's stock price target for 2024?: 5 Wall Street analysts have issued twelve-month price targets for Ocuphire Pharma's shares. Their OCUP share price targets range from $17.00 to $20.00. On average, they expect the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 983.8% from the stock's current price.
View analysts price targets for OCUP or view top-rated stocks among Wall Street analysts.
How have OCUP shares performed in 2024?: Ocuphire Pharma's stock was trading at $3.01 at the start of the year. Since then, OCUP stock has decreased by 42.5% and is now trading at $1.73.
View the best growth stocks for 2024 here.
When is Ocuphire Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our OCUP earnings forecast.

How were Ocuphire Pharma's earnings last quarter?: Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its earnings results on Friday, March, 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.14. The business had revenue of $1.69 million for the quarter, compared to analyst estimates of $3.47 million. Ocuphire Pharma had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 24.57%.
Who are Ocuphire Pharma's major shareholders?: Ocuphire Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.87%), Rice Hall James & Associates LLC (1.18%), Richmond Brothers Inc. (0.89%), Empowered Funds LLC (0.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include George Magrath, James S J Manuso, Jay Pepose, Joseph K Schachle, Mina Sooch and Nirav S Jhaveri.
View institutional ownership trends.
How do I buy shares of Ocuphire Pharma?: Shares of OCUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUP) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Ocuphire Pharma (OCUP) Stock Price, News & Analysis

Ocuphire Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Book Value per Share Ratio

About Ocuphire Pharma Stock (NASDAQ:OCUP)

OCUP Stock Price History

OCUP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OCUP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™